FDA Approves First PROTAC Vepdegestrant (ARV-471) for ER+/HER2- Breast Cancer, Ushering in a New Era of Targeted Protein Degradation

August 2, 2026

Journal of Medicinal Chemistry – ACS Publications USA

Overview

On May 1, 2026, the FDA approved vepdegestrant (ARV-471; Veppanu), making it the first heterobifunctional PROTAC protein degrader approved for clinical practice. Indicated for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, this approval validates targeted protein degradation (TPD) as a clinically viable therapeutic modality. Vepdegestrant demonstrated favorable oral bioavailability, a well-tolerated safety profile, and clinically significant efficacy by improving progression-free survival over fulvestrant.

In Depth

Key Findings

On May 1, 2026, the U.S. Food and Drug Administration (FDA) granted approval to vepdegestrant (ARV-471; brand name Veppanu). This landmark decision establishes vepdegestrant as the first heterobifunctional PROTAC (Proteolysis-Targeting Chimera) protein degrader to enter clinical practice, specifically for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. This approval marks a pivotal moment, validating targeted protein degradation (TPD) as a clinically viable and impactful therapeutic modality in oncology.

Technical / Clinical Details

Vepdegestrant selectively targets the estrogen receptor (ER), leveraging the cell’s intrinsic ubiquitin-proteasome system to degrade the ER protein. This mechanism fundamentally differs from traditional ER inhibitors or selective estrogen receptor degraders (SERDs), as it actively removes the ER protein, potentially overcoming resistance mechanisms and achieving deeper ER suppression. In clinical trials, vepdegestrant exhibited favorable oral bioavailability and a well-tolerated safety profile. Crucially, it demonstrated a statistically significant improvement in progression-free survival (PFS) compared to fulvestrant, the standard of care, particularly in patient populations with ESR1 mutations, underscoring its clinical utility.

Background & Context

Breast cancer is one of the most common cancers among women, with ER-positive breast cancer accounting for approximately 70% of all cases. While hormone therapy is a primary treatment, drug resistance, often driven by ESR1 mutations, has remained a significant challenge. The PROTAC concept, first proposed in the early 2000s, has garnered attention for its innovative approach of directly degrading disease-associated proteins, yet clinical translation had been elusive. Vepdegestrant’s approval unequivocally demonstrates that PROTAC technology has moved beyond proof-of-concept to become a practical therapeutic agent capable of providing tangible patient benefits. This success is expected to catalyze the development of numerous other PROTAC candidates.

Strategic Significance & Outlook

The approval of vepdegestrant heralds a new era for the targeted protein degradation field. Moving forward, PROTAC technology is expected to accelerate the development of treatments for various diseases beyond ER-positive breast cancer, especially for cancers with high expression of target proteins and for ‘undruggable’ targets that have proven recalcitrant to conventional inhibitors. Further advancements in PROTAC design optimization, improving oral bioavailability, and enhancing target selectivity are anticipated, potentially leading to a wave of more effective and safer degraders. The growth in this domain will drive innovation across the pharmaceutical industry, offering new therapeutic options to address unmet medical needs globally.

Source: https://pubs.acs.org/doi/10.1021/acs.jmedchem.6c02076

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.